Robert W. Baird Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price target cut by Robert W. Baird from $27.00 to $26.00 in a report issued on Monday, Benzinga reports. They currently have an outperform rating on the stock.

AVTR has been the topic of several other reports. Wells Fargo & Company assumed coverage on Avantor in a research report on Tuesday, August 27th. They set an “overweight” rating and a $30.00 price target on the stock. UBS Group reduced their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, October 8th. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and lowered their price target for the company from $30.00 to $23.00 in a research report on Wednesday, July 10th. Morgan Stanley boosted their price objective on shares of Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Finally, TD Cowen raised their target price on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Avantor has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Avantor Stock Performance

Shares of AVTR opened at $22.37 on Monday. The company has a 50-day simple moving average of $25.26 and a two-hundred day simple moving average of $24.19. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The firm has a market capitalization of $15.20 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 2.93 and a beta of 1.33. Avantor has a one year low of $17.06 and a one year high of $28.00.

Insider Activity

In related news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Avantor

Large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC grew its stake in shares of Avantor by 113.0% during the 1st quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock valued at $63,857,000 after purchasing an additional 1,325,026 shares during the period. Swedbank AB purchased a new stake in Avantor during the first quarter valued at approximately $2,707,000. Diversify Advisory Services LLC bought a new position in Avantor in the first quarter worth approximately $908,000. BNP Paribas Financial Markets boosted its stake in shares of Avantor by 42.4% during the 1st quarter. BNP Paribas Financial Markets now owns 309,394 shares of the company’s stock worth $7,911,000 after acquiring an additional 92,098 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its stake in shares of Avantor by 44.6% during the 1st quarter. William Blair Investment Management LLC now owns 1,047,732 shares of the company’s stock worth $26,791,000 after acquiring an additional 322,985 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.